Margarit Daiana-Andreea, Stanca Horia Tudor, Mocanu Valeria, Munteanu Mihnea, Ferrari Francis, Marius Suta
Ophthalmology Department, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Ophthalmology Department, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
J Clin Med. 2024 Oct 17;13(20):6182. doi: 10.3390/jcm13206182.
This study aims to evaluate the efficacy, safety, and predictability of Transepithelial Photorefractive Keratectomy (TPRK) using the SmartPulse technology excimer laser for the correction of myopia and myopic astigmatism, assessing visual and refractive outcomes over a one-year follow-up period. This retrospective cohort study analyzed data from patients who underwent TPRK at the Ophthalmology Department-"Victor Babes" University of Medicine and Pharmacy in Timisoara (Romania), between January 2019 and June 2023. The procedure was performed using the SmartPulse Technology of the SmartSurf AMARIS 750S excimer laser (SCHWIND eye-tech-solutions, Kleinostheim, Germany). Preoperative assessments included visual acuity, refraction, and corneal measurements, with postoperative evaluations conducted for up to 12 months. This study included 92 eyes from 46 patients (mean age 29.02 years, 63% male). At 12 months post-op, 100% achieved UDVA 20/25 or better, with an efficacy index of 1.01. Refractive accuracy was 96% within ±0.50 D of the target and astigmatism ≤ 0.50 D in 99% of eyes. The safety index was 1.01. Corneal haze occurred in 8.70% of eyes and was effectively managed with dexamethasone drops. TPRK with the SmartPulse technology excimer laser demonstrated high efficacy and safety in correcting myopia and myopic astigmatism, achieving stable visual outcomes over one year. The procedure also showed excellent predictability with a low incidence of complications, supporting its use as a reliable refractive surgery option.
本研究旨在评估使用SmartPulse技术准分子激光的经上皮光屈光性角膜切削术(TPRK)矫正近视和近视散光的疗效、安全性和可预测性,并在一年的随访期内评估视觉和屈光结果。这项回顾性队列研究分析了2019年1月至2023年6月期间在罗马尼亚蒂米什瓦拉“维克托·巴比什”医科药科大学眼科接受TPRK手术的患者数据。手术使用SmartSurf AMARIS 750S准分子激光(德国克莱诺施泰姆的SCHWIND眼科技解决方案公司)的SmartPulse技术进行。术前评估包括视力、验光和角膜测量,术后评估持续12个月。本研究纳入了46例患者的92只眼(平均年龄29.02岁,男性占63%)。术后12个月时,100%的患者达到20/25或更好的最佳矫正视力,疗效指数为1.01。屈光精度在目标值±0.50 D范围内的为96%,99%的眼睛散光≤0.50 D。安全指数为1.01。8.70%的眼睛出现角膜 haze,用地塞米松滴眼液有效处理。使用SmartPulse技术准分子激光的TPRK在矫正近视和近视散光方面显示出高疗效和安全性,在一年中实现了稳定的视觉结果。该手术还显示出极佳的可预测性,并发症发生率低,支持其作为一种可靠的屈光手术选择。